Abiraterone acetate (Zytiga®) for the treatment of newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 03/10/2018 |
| Rapid review completed | 15/11/2018 |
| Rapid Review outcome | A full pharmacoeconomic assessment is recommended |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.